The Spectranetics — Spectranetics — Charing Cross 2016
19 slides from The Spectranetics's conference presentation, Apr 26, 2016
Slide 1: ILLUMENATE Global Study Interim Analysis
Charing Cross 2016 Prof. Thomas Zeller Department of Angiology University Heart Center Freiburg‐ Bad Krozingen Bad Krozingen, Germany On behalf of Dr. Andrew Holden, Prof. Yann Gouëffic and the ILLUMENATE Global Investigators ILLUMENATE Global Study Interim Analysis
Slide 2: Disclosure
Charing Cross 2016 Disclosure Speaker name: Prof. Thomas Zeller ................................................................................. I have the following potential conflicts of interest to report: Receipt of grants/research support Receipt of honoraria and travel support Partici
Slide 3: ILLUMENATE (SFA) Clinical Program: 6 Studies, 6000+ Patients
Charing Cross 2016 ILLUMENATE (SFA) Clinical Program 6 Studies: 6000+ Patients
Slide 4: ILLUMENATE Global Study Overview
Charing Cross 2016 ILLUMENATE Global Study Overview Prospective, multi‐center, single‐arm, study Patients will be followed for up to 5 years Same rigorous data collection process as randomized trials, independent adjudication by: • Angiographic Core Laboratory1 • Duplex Ultrasound Core Laborator
Slide 5: ILLUMENATE Global Study Overview: Objective and Endpoints
Charing Cross 2016 ILLUMENATE Global Study Overview Study Objective: Assess safety and performance of the Stellarex DCB in the SFA and/or popliteal arteries Primary Safety Endpoint: Freedom from device‐ and procedure‐related death through 30 days and freedom from target limb major amputation and
Slide 6: Study Device: Stellarex DCB
Charing Cross 2016 • Low dose paclitaxel, 2 µg/mm2 • Excipient: Polyethylene Glycol (PEG) • Proprietary open‐folded coating technology • High coating stability • Limited drug loss • Effective drug tissue transfer and residency ( 28 days) Stellarex (2 µgr/mm2) DCB Comp. A (3.5 µgr/mm2) DCB Comp. B (
Slide 7: Key Patient Eligibility Criteria
Charing Cross 2016 Key Patient Eligibility Criteria Inclusion Criteria • Rutherford class 2, 3 or 4 • SFA and/or popliteal (down to trifurcation) • Has at least one patent run‐ off below‐the‐knee • 1 or 2 target lesion(s) with cumulative length ≤ 20 cm • Target vessel reference diameter 4‐6 mm Exclu
Slide 8: Interim Analysis
Charing Cross 2016 Interim Analysis The following Interim analysis includes data on the first 153 subjects who have been seen for their 12 month follow‐up visit N=153 subjects (of the 371 enrolled) All presented data/images were monitored, adjudicated and assessed by the appropriate core lab a
Slide 9: Baseline Patient Characteristics
Charing Cross 2016 Baseline Patient Characteristics N (patients) 153 Age 69.3 ± 9.6 (153) Male 72.5% (111/153) Diabetes 35.3% (54/153) Body Mass Index 27.1 ± 4.1 (152) Hypertension 75.8% (116/153) Hyperlipidemia 75.8% (116/153) Current smoker 37.3% (57/153) Previous coronary revasc. 37.3% (57/153) R
Slide 10: Baseline Angiographic Characteristics
Charing Cross 2016 Baseline Angiographic Characteristics N (lesions) 174 De novo1 94.3% (164/174) Lesion Length (cm) 7.3 ± 5.0 (172) Total occlusions 25.6% (44/172) Calcification None/Mild 37.8% (65/172) Moderate 19.8% (34/172) Severe calcification2 42.4% (73/172) Minimum lumen diameter (mm) 1.1 ± 0
Slide 11: Procedural Characteristics
Charing Cross 2016 Procedural Characteristics Pre‐dilatation1 98.9% (172/174) Post‐dilatation1 25.3% (44/174) Provisional stent1 12.6% (22/174) Stent Due to Dissection1 7.5% (13/174) Post‐procedural Dissections Grade D Flow‐limiting (Grade E or F) 16.3% (28/172) 0% (0/172) Post‐procedure MLD (mm) 3.
Slide 12: Interim 12-Month Safety Outcomes
Charing Cross 2016 Interim 12 Month Safety Outcomes Freedom from Primary Safety Event: 91.0% 12‐month all‐cause mortality rate: 0.7% (1/143) Cause of death: pancreatic cancer Primary Safety Outcome Component Device‐ or procedure‐related death 0 Major target limb amputation 1 (Patient RCC 5 at
Slide 13: Freedom From CD-TLR by Clinical Events Committee Adjudication
Charing Cross 2016 Freedom From CD‐TLR* by Clinical Events Committee Adjudication * Defined as revascularization associated with PSVR ≥ 2.5 or >50% stenosis via angiogram and worsening of RCC by more than 1 or ABI decrease of >0.15 from the maximum early post-procedure level, that is clearly referab
Slide 14: Freedom From Loss of Primary Patency by Duplex Core Lab Evaluation
Charing Cross 2016 Freedom From Loss of Primary Patency by Duplex Core Lab Evaluation Primary Patency defined as freedom from Duplex derived restenosis (PSVR ≤ 2.5) and clinically-driven TLR Number at risk at day 395 is 39 since follow-up is still in progress Day 0 30 360 365 395 At Risk 174 171 161
Slide 15: ILLUMENATE Global Interim Data In Context with Core Lab Adjudicated Patency Rates
Charing Cross 2016 ILLUMENATE Global Interim Data In Context with Core Lab* Adjudicated Patency Rates Schroeder H, et al. Catheter Cadiovasc Interv 86;278‐286 (2015). Tepe G. IN.PACT SFA 1‐year primary outcomes. Oral presentation . Charing Cross. April 5–8, 2014. London, UK, 2014. Rosenfield K, Jaff
Slide 16: Functional Outcomes: ABI and Rutherford Classification
Charing Cross 2016 0% 1% 30% 57% 8% 4% 63% 23% 7% 6% 0% 1% RCC 0 RCC 1 RCC 2 RCC 3 RCC 4 RCC 5 Baseline 12 Months Functional Outcomes 0.72 0.93 0.92 0 0.2 0.4 0.6 0.8 1 1.2 Baseline n=139 6 months n=125 12 months n=121 Mean ABI Rutherford Classification* 74.8% of subjects had an improvement in ABI
Slide 17: Functional Outcomes: Walking Impairment Questionnaire (WIQ)
Charing Cross 2016 Functional Outcomes: Walking Impairment Questionnaire (WIQ) Mean WIQ Scores* *analysis includes only patients with WIQ data at baseline and 12 months (n=135) 29.4 22.7 41.2 30.9 71.9 48.6 64.2 61.2 Walking Distance Score Walking Speed Score Stair Climbing Score Composite WIQ Score
Slide 18: Conclusions
Charing Cross 2016 Conclusions • Interim 12‐Month patency rate: 88.5% at day 360 and 84.7% at day 365 • Consistent with ILLUMENATE FIH • Matching best‐in‐class reported outcomes to date • Interim 12‐Month CD‐TLR Free rate: 91.0% • Significant gains in functional outcomes achieved • No safety signals
Slide 19: ILLUMENATE Global Study Interim Analysis
Charing Cross 2016 Prof. Thomas Zeller Department of Angiology University Heart Center Freiburg‐ Bad Krozingen Bad Krozingen, Germany On behalf of Dr. Andrew Holden, Prof. Yann Gouëffic and the ILLUMENATE Global Investigators ILLUMENATE Global Study Interim Analysis